drugset / Trial / NCT00623714

Induced Sputum Study (0000-065)

NCT00623714

Phase 1 Completed 13 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. The results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics.

Timeline

Start
2008-01
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 500 ug Inhaled

Indications